BioPartners Submits an Application for Approval of Valtropin (TM) a Recombinant Human Growth Hormone in Europe.
PR Newswire Europe, November, 2004
ZUG, Switzerland, November 29 /PRNewswire/ -- BioPartners, a global biopharmaceuticals company and one of the leaders in the emerging field of competitively priced biosimilar products has submitted a marketing authorisation application (MAA) to the European Medicines Evaluation Agency (EMEA) for Valtropin(TM) (somatropin), its recombinant human growth hormone developed in collaboration with LG Life Sciences (LGLS) of Korea.
The application for Valtropin in the treatment of paediatric and adult growth hormone deficiency (GHD) and other growth disorders is currently under ...
Most Recent Business Articles
- How do I determine my retainer fee?
- Why fly solo when an executive assistant can accelerate your CLNC® business?
- The CLNC® mentors held the key to my first case and to my CLNC® success
- Atlanta CLNC® 6-day certification seminar photo gallery—plus sign up today for spring 2009 to save $100.00
- Speak to a full-time practicing CLNC® consultant
Most Recent Business Publications
Most Popular Business Articles
- Using object-oriented analysis and design over traditional structured analysis and design
- Big Fish Games Migrates Upstream to Fisher Plaza; High Growth Online Gaming Firm Vaults Fisher Plaza Occupancy Rate Above 90%
- Top of the line: some of the world's most well-respected doctors practice in South Florida. A guide to choosing the best physician specialists - Top Doctors in South Florida
- Sand filter basics: high-rate sand filters can be confusing for those new to the business. Understanding valve modes is the key
- BEHR Paints Introduces a Colorful New Way to Paint and Prime All in One with BEHR Premium Plus Ultra™ Interior
Sponsored by Merrill Lynch